Compare
Incyte Corp vs Icon PLC vs MaxCyte, Inc. vs iSpecimen Inc.
| Latest fiscal year | Incyte Corp INCY | Icon PLC ICLR | MaxCyte, Inc. MXCT | iSpecimen Inc. ISPC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $5.14B | $8.25B | $33.03M | $1.93M |
| Revenue growth (YoY) | +21.2% | +0.8% | -14.5% | -79.2% |
| Gross margin | 92.8% (computed) | n/a | 81.2% | 1.2% (computed) |
| Operating margin | 29.5% | 5.4% | -157.1% | -465.4% |
| Net margin | 25.0% | 2.8% | -135.1% | -543.7% |
| Net income | $1.29B | $229.34M | -$44.63M | -$10.49M |
| EPS (Diluted) | $6.41 | $2.90 | -$0.42 | -$2.28 |
| Operating cash flow | $1.41B | $1.04B | -$34.41M | -$4.24M |
| Free cash flow | n/a | $861.99M | -$36.18M | -$4.24M |
| Cash & equivalents | $3.10B | $647.29M | $20.07M | $6.88M |
| Total assets | $6.96B | $16.27B | $202.51M | $9.53M |
| Total liabilities | $1.79B | $7.08B | $31.02M | $6.44M |
| Shareholders' equity | $5.17B | $9.19B | $171.49M | $3.09M |
| Return on year-end equity | 24.9% | 2.5% | -26.0% | -339.6% |
| Shares outstanding | 198.46M | 76.57M | 106.79M | 8.48M |
Revenue, most recent five fiscal years
| Fiscal year | Incyte Corp | Icon PLC | MaxCyte, Inc. | iSpecimen Inc. |
|---|---|---|---|---|
| Latest | $5.14B Ended 2025-12-31 | $8.25B Ended 2025-12-31 | $33.03M Ended 2025-12-31 | $1.93M Ended 2025-12-31 |
| 1 year earlier | $4.24B Ended 2024-12-31 | $8.19B Ended 2024-12-31 | $38.63M Ended 2024-12-31 | $9.29M Ended 2024-12-31 |
| 2 years earlier | $3.70B Ended 2023-12-31 | $8.05B Ended 2023-12-31 | $41.29M Ended 2023-12-31 | $9.93M Ended 2023-12-31 |
| 3 years earlier | $3.39B Ended 2022-12-31 | $7.74B Ended 2022-12-31 | $44.26M Ended 2022-12-31 | $10.40M Ended 2022-12-31 |
| 4 years earlier | $2.99B Ended 2021-12-31 | $5.48B Ended 2021-12-31 | $33.89M Ended 2021-12-31 | $11.14M Ended 2021-12-31 |